Valuation
- Market cap
- 1,996,000
- Revenue TTM
- $10,000
- Net income TTM
- $-4,180,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- -41,800.00%
- Debt to equity
- 0.00
Trading
- Volume
- 3,420,400
- Avg volume
- 1,087,490
- Day's range
- $0.77 – $1.05
- Shares out
- 2,540,000
- Stochastic %K
- 100%
- Beta
- -0.87
- Analysts
- Strong Buy
- Price target
- $3.00
Company profile
Alaunos Therapeutics, Inc., a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders. It develops non-hormonal, non-incretin approach, and unlike hormone-based treatments, such as GLP-1 drugs. The company also develops hunTR TCR discovery platform to target driver mutations. Alaunos Therapeutics, Inc. was...
Show more
Alaunos Therapeutics, Inc., a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders. It develops non-hormonal, non-incretin approach, and unlike hormone-based treatments, such as GLP-1 drugs. The company also develops hunTR TCR discovery platform to target driver mutations. Alaunos Therapeutics, Inc. was founded in 2003 and is based in Fort Lauderdale, Florida.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 346 355 4099
- Website
- https://www.alaunos.com
- Address
- 501 E. Las Olas Blvd., Suite 300, Fort Lauderdale, United States
Latest news
No headlines yet.
